Hypertension

This page includes news and new technology on hypertension. The condition is caused by abnormally high blood pressure that causes excess force and pressure of the blood against the artery walls. Long-term, this can cause damage the vessels and contributes to heart disease. Therapies include antihypertensive medications such as diurestics and renal denervation therapy.

Royal Philips has announced the debut of a comprehensive approach to telehealth with Philips Virtual Care Management. The solution’s condition-specific protocols now include heart disease and hypertension, as well as other chronic conditions. Photo credit: Getty Images

News | Remote Monitoring

Philips Debuts Remote Patient Management Solution

March 28, 2023 — Royal Philips has announced its debut of Philips Virtual Care Management, a comprehensive approach to ...

March 28, 2023

Use of an antihypertensive to lower blood pressure in obese patients was found effective, according to Target-HTN Trial results presented during the 2023 American College of Cardiology Scientific Session.

News | ACC

Data from Target-HTN Trial Released at ACC23 Supports Use of Antihypertensive to Reduce Blood Pressure in Obese Patients

March 9, 2023 — Positive results from a Mineralys Therapeutics study, the Target-HTN Phase 2 trial, demonstrated ...

March 09, 2023

Kelly Chin, MD, professor of medicine and director of the pulmonary hypertension program at UT Southwestern Medical Center in Dallas

News | Hypertension

Fixed-Dose Combination Pill Outperforms Monotherapy for Pulmonary Hypertension

March 6, 2023 — Patients with pulmonary arterial hypertension (high blood pressure in the arteries that supply the lungs ...

March 06, 2023

Amrita Mukhopadhyay, MD, cardiologist and clinical investigator at NYU Grossman School of Medicine in New York City

News | Heart Failure

Prescribing of Key Heart Failure Medications Improved with Tailored Digital Alerts

March 5, 2023 — Doctors who received customized electronic health record (EHR) alerts for specific patients were 2.5 ...

March 05, 2023

Primary Results from RADIANCE II Trial Published in JAMA and Results of Pooled Analysis from Three RADIANCE Studies Published in JAMA Cardiology

News | Renal Denervation

ReCor Medical Announces Two Concurrent JAMA Network Publications of Study Results on the Paradise Ultrasound Renal Denervation System for the Treatment of Hypertension

March 2, 2023 — ReCor Medical, Inc. and its parent company, Otsuka Medical Devices Co., Ltd. announced that primary ...

March 02, 2023

The risk of hypertension increases significantly with orthostatic circulatory disorders.

News | Hypertension

RUDN University Doctors Tested a Novel Approach to Detecting Future Arterial Hypertension in Healthy People

January 17, 2023 — Arterial hypertension(AH), or high blood pressure, can be prevented if diagnosed pre-clinically on ...

January 17, 2023

CinCor Pharma, Inc. announced that it has entered into a definitive agreement with AstraZeneca under which AstraZeneca has agreed to acquire CinCor.

News | Cardiovascular Business

CinCor Pharma to be Acquired by AstraZeneca

January 9, 2023 — CinCor Pharma, Inc. announced that it has entered into a definitive agreement with AstraZeneca under ...

January 09, 2023

News | Cardiovascular Business

ReCor Medical Names Lara Barghout President and Chief Executive Officer

January 9, 2023 — ReCor Medical, Inc. and its parent company, Otsuka Medical Devices Co., Ltd. announced the appointment ...

January 09, 2023

News | Clinical Decision Support

Computerized Decision Support System Helps to Reduce Cardiovascular Risk Factors in Patients with Diabetes

December 7, 2022 — Compared with team-based care alone, the addition of a computerized clinical decision support system ...

December 07, 2022

Nicholas Pajewski, Ph.D., associate professor of biostatistics and data science at Wake Forest University School of Medicine. Credit: Wake Forest University School of Medicine

News | Hypertension

Study Highlights Importance of Long-term Management of Hypertension

November 23, 2022 — In 2015, published findings from the landmark Systolic Blood Pressure Intervention Trial (SPRINT) sh ...

November 23, 2022

Successfully Met Primary and Secondary Endpoints, with Mean Placebo-Adjusted Reduction in Systolic Blood Pressure of 9.7 mmHg in Uncontrolled and Resistant Hypertensive Subjects at 50 mg Once Daily (p=0.01 vs. placebo)

News | Hypertension

Mineralys Therapeutics Announces Positive Topline Phase 2 Data for MLS-101 in the Target-HTN Trial Evaluating the Treatment of Uncontrolled and Resistant Hypertension

November 21, 2022 — Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company committed to ...

November 21, 2022

News | Hypertension

Mineralys Therapeutics Announces Positive Topline Phase 2 Data for MLS-101 in the Target-HTN Trial Evaluating the Treatment of Uncontrolled and Resistant Hypertension

November 21, 2022 — Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company committed to ...

November 21, 2022

Risk Reductions of 46% to 52% for Heart Failure Readmissions and for Composite of CV Death and Heart Failure Readmissions at 30- and 90-Days Following Hospital Discharge

News | Hypertension

CinCor Pharma Announces Late-Breaking Presentation of Phase 2 BrigHtn Data on Baxdrostat in Treatment-Resistant Hypertension at the 2022 American Heart Association Scientific Sessions

November 9, 2022 — CinCor Pharma, Inc. announced the presentation today of Phase 2 data from its BrigHtn trial as part ...

November 09, 2022

CinCor Pharma, Inc. announced the publication of Phase 1 clinical data for baxdrostat, a highly selective, once daily, oral small molecule inhibitor of aldosterone synthase, in the journal Hypertension Research.

News | Hypertension

CinCor Pharma Announces Publication of Phase 1 Multiple Ascending Dose Study Data in Hypertension Research

October 24, 2022 — CinCor Pharma, Inc. announced the publication of Phase 1 clinical data for baxdrostat, a highly ...

October 24, 2022

The data, collected during the transition from intravenous (IV) to oral levosimendan in the open-label extension (OLE) of the HELP (Hemodynamic Evaluation of Levosimendan in PH-HFpEF) trial, were presented at the Heart Failure Society of America (HFSA) Scientific Sessions 2022

News | Heart Failure

Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

October 13, 2022 — Tenax Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing, and ...

October 13, 2022